Revolutionizing immuno-oncology, the technology enables antibody-based therapies to target mutated cancer-causing and viral proteins inside cells. It utilizes a protein-display system to discover antibodies against challenging peptide-MHC complexes, significantly increasing the number of cancer or viral targets.